Immunome Inc (IMNM)

Apr 17, 2025, 6:06 AM EDT - 3 days ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 4, 2025, 8:00 AM EDT - 16 days ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 4:05 PM EDT - 17 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2025, 4:05 PM EDT - 4 weeks ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 7:41 AM EDT - 5 weeks ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Feb 25, 2025, 8:00 AM EST - 7 weeks ago

Immunome to Present at Upcoming March Conferences

Jan 31, 2025, 4:01 PM EST - 2 months ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2025, 10:27 AM EST - 2 months ago

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 29, 2025, 11:11 PM EST - 2 months ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 4:27 PM EST - 2 months ago

Immunome Announces Proposed Public Offering of Common Stock

Jan 13, 2025, 8:00 AM EST - 3 months ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 5 months ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 5 months ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 8:00 AM EST - 5 months ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 6 months ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 18, 2024, 8:00 AM EDT - 6 months ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 8, 2024, 8:05 AM EDT - 6 months ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Sep 13, 2024, 7:00 AM EDT - 7 months ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 29, 2024, 8:00 AM EDT - 8 months ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 8 months ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 25, 2024, 8:00 AM EDT - 9 months ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jun 27, 2024, 2:14 PM EDT - 10 months ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 8:00 AM EDT - 10 months ago

Immunome Appoints Phil Tsai as Chief Technical Officer

May 20, 2024, 8:00 AM EDT - 11 months ago

Immunome Announces Completion of Purchase of Assets from Atreca

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

May 2, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Kinney Horn as Chief Business Officer

Apr 25, 2024, 8:26 AM EDT - 1 year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 2, 2024, 2:07 PM EDT - 1 year ago

Immunome: An Oncology Powerhouse In The Making

Mar 28, 2024, 4:02 PM EDT - 1 year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 18, 2024, 5:44 AM EDT - 1 year ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 7, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Feb 20, 2024, 8:15 AM EST - 1 year ago

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Feb 16, 2024, 4:05 PM EST - 1 year ago

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 13, 2024, 10:38 PM EST - 1 year ago

Immunome Announces Pricing of Public Offering of Common Stock

Feb 6, 2024, 8:00 AM EST - 1 year ago

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Feb 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 7:00 AM EST - 1 year ago

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

ZNTL

Jan 4, 2024, 8:00 AM EST - 1 year ago

Immunome Appoints Phil Roberts as Chief Technical Officer

Jan 3, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

Immunome Appoints Carol A. Schafer to Board of Directors

Dec 26, 2023, 8:30 AM EST - 1 year ago

Immunome to Acquire Antibody-Related Assets and Materials from Atreca

Nov 10, 2023, 8:00 AM EST - 1 year ago

Immunome to Present at the Stifel 2023 Healthcare Conference

Nov 9, 2023, 8:00 AM EST - 1 year ago

Immunome Reports Third Quarter 2023 Financial Results

Nov 8, 2023, 8:00 AM EST - 1 year ago

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer